STAAR Surgical (STAA)

Executive Summary

STAAR Surgical is the leading developer and manufacturer of implantable collamer lenses (ICL) for vision correction. With over 4 million lenses sold globally, the company's proprietary Collamer material offers a unique combination of biocompatibility and optical clarity, positioning EVO ICL as a premium alternative to LASIK and contact lenses. Operating in over 75 countries, STAAR has established a strong foothold in Asia-Pacific, particularly China and Japan, where myopia prevalence is high. The company continues to invest in R&D to expand indications, including presbyopia-correcting lenses, and to enhance its manufacturing efficiency. Financially, STAAR has demonstrated consistent revenue growth driven by increasing adoption of EVO ICL, though profitability remains pressured by R&D and commercialization expenses. Key risks include regulatory delays, competition from refractive surgery and intraocular lenses, and reliance on a single product line. However, a robust pipeline and expanding geographic footprint support long-term growth prospects. The company's valuation reflects its market leadership in the implantable lens space, with upside potential from upcoming regulatory milestones and market expansions.

Upcoming Catalysts (preview)

• Q4 2026FDA approval for EVO ICL in presbyopia correction70% success
• Q2 2026China NMPA approval for next-generation ICL85% success
• Q2 2026Q1 2026 earnings report with revenue guidance95% success